1
|
Xiao L, Li Y, Geng R, Chen L, Yang P, Li M, Luo X, Yang Y, Li L, Cai H. Polymer composite microspheres loading 177Lu radionuclide for interventional radioembolization therapy and real-time SPECT imaging of hepatic cancer. Biomater Res 2023; 27:110. [PMID: 37925456 PMCID: PMC10625707 DOI: 10.1186/s40824-023-00455-x] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2023] [Accepted: 10/24/2023] [Indexed: 11/06/2023] Open
Abstract
BACKGROUND Transarterial radioembolization (TARE) with 90Y-labeled glass and resin microspheres is one of the primary treatment strategies for advanced-stage primary and metastatic hepatocellular carcinoma (HCC). However, difficulties of real-time monitoring post administration and embolic hypoxia influence treatment prognosis. In this study, we developed a new biodegradable polymer microsphere that can simultaneously load 177Lu and MgO nanoparticle, and evaluated the TARE therapeutic efficacy and biosafety of 177Lu-PDA-CS-MgO microspheres for HCC treatment. METHODS Chitosan microspheres were synthesized through emulsification crosslink reaction and then conducted surface modification with polydopamine (PDA). The 177Lu and nano MgO were conjugated to microspheres using active chemical groups of PDA. The characteristics of radionuclide loading efficiency, biodegradability, blood compatibility, and anti-tumor effectwere evaluated both in vitro and in vivo. SPECT/CT imaging was performed to monitor bio-distribution and bio-stability of 177Lu-PDA-CS-MgO after TARE treatment. The survival duration of each rat was monitored. HE analysis, TUNEL analysis, immunohistochemical analysis, and western blot analysis were conducted to explore the anti-tumor effect and mechanism of composited microspheres. Body weight, liver function, blood routine examination were monitored at different time points to evaluate the bio-safety of microspheres. RESULTS The composite 177Lu-PDA-CS-MgO microsphere indicated satisfactory degradability, biocompatibility, radionuclide loading efficiency and radiochemical stability in vitro. Cellular evaluation showed that 177Lu-PDA-CS-MgO had significant anti-tumor effect and blocked tumor cell cycles in S phase. Surgical TARE treatment with 177Lu-PDA-CS-MgO significantly prolonged the medial survival time from 49 d to 105 d, and effectively inhibited primary tumor growth and small metastases spreading. Moreover, these microspheres indicated ideal in vivo stability and allowed real-time SPECT/CT monitoring for up to 8 weeks. Immunostaining and immunoblotting results also confirmed that 177Lu-PDA-CS-MgO had potential in suppressing tumor invasion and angiogenesis, and improved embolic hypoxia in HCC tissues. Further evaluations of body weight, blood test, and pathological analysis indicated good biosafety of 177Lu-PDA-CS-MgO microspheres in vivo. CONCLUSION Our study demonstrated that 177Lu-PDA-CS-MgO microsphere hold great potential as interventional brachytherapy candidate for HCC therapy. Polymer composite microspheres loading 177Lu radionuclide and MgO nanoparticles for interventional radioembolization therapy and real-time SPECT imaging of hepatic cancer.
Collapse
Affiliation(s)
- Liu Xiao
- Department of Nuclear Medicine & Laboratary of Clinical Nuclear Medicine, West China Hospital, Sichuan University, Chengdu, 610041, P.R. China
| | - Yuhao Li
- Department of Nuclear Medicine & Laboratary of Clinical Nuclear Medicine, West China Hospital, Sichuan University, Chengdu, 610041, P.R. China
| | - Ruiman Geng
- Department of Biochemistry & Molecular Biology, West China School of Basic Sciences & Forensic Medicine, Sichuan University, Chengdu, 610041, China
| | - Lihong Chen
- Department of Biochemistry & Molecular Biology, West China School of Basic Sciences & Forensic Medicine, Sichuan University, Chengdu, 610041, China
| | - Peng Yang
- College of Polymer Science and Engineering, State Key Laboratory of Polymer Materials Engineering, Sichuan University, Chengdu, 610065, P.R. China
| | - Mingyu Li
- School of New Energy and Materials, Southwest Petroleum University, Chengdu, 610500, P.R. China
| | - Xia Luo
- School of New Energy and Materials, Southwest Petroleum University, Chengdu, 610500, P.R. China
| | - Yuchuan Yang
- Institute of Nuclear Physics and Chemistry, China Academy of Engineering Physics, Mianyang, 621900, P.R. China
| | - Lin Li
- Department of Nuclear Medicine & Laboratary of Clinical Nuclear Medicine, West China Hospital, Sichuan University, Chengdu, 610041, P.R. China.
| | - Huawei Cai
- Department of Nuclear Medicine & Laboratary of Clinical Nuclear Medicine, West China Hospital, Sichuan University, Chengdu, 610041, P.R. China.
| |
Collapse
|
2
|
Johnson K, Driscoll DM, Damron JT, Ivanov AS, Jansone-Popova S. Size Selective Ligand Tug of War Strategy to Separate Rare Earth Elements. JACS AU 2023; 3:584-591. [PMID: 36873676 PMCID: PMC9976341 DOI: 10.1021/jacsau.2c00671] [Citation(s) in RCA: 8] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/09/2022] [Revised: 01/09/2023] [Accepted: 01/13/2023] [Indexed: 05/08/2023]
Abstract
Separating rare earth elements is a daunting task due to their similar properties. We report a "tug of war" strategy that employs a lipophilic and hydrophilic ligand with contrasting selectivity, resulting in a magnified separation of target rare earth elements. Specifically, a novel water-soluble bis-lactam-1,10-phenanthroline with an affinity for light lanthanides is coupled with oil-soluble diglycolamide that selectively binds heavy lanthanides. This two-ligand strategy yields a quantitative separation of the lightest (e.g., La-Nd) and heaviest (e.g., Ho-Lu) lanthanides, enabling efficient separation of neighboring lanthanides in-between (e.g., Sm-Dy).
Collapse
Affiliation(s)
- Katherine
R. Johnson
- Nuclear
Energy and Fuel Cycle Division, Oak Ridge
National Laboratory, Oak Ridge, Tennessee 37831, United States
| | - Darren M. Driscoll
- Chemical
Sciences Division, Oak Ridge National Laboratory, Oak Ridge, Tennessee 37831, United States
| | - Joshua T. Damron
- Chemical
Sciences Division, Oak Ridge National Laboratory, Oak Ridge, Tennessee 37831, United States
| | - Alexander S. Ivanov
- Chemical
Sciences Division, Oak Ridge National Laboratory, Oak Ridge, Tennessee 37831, United States
| | - Santa Jansone-Popova
- Chemical
Sciences Division, Oak Ridge National Laboratory, Oak Ridge, Tennessee 37831, United States
| |
Collapse
|
3
|
Electrochemical Separation and Purification of No-Carrier-Added 177Lu for Radiopharmaceutical Preparation: Translation from Bench to Bed. CHEMICAL ENGINEERING JOURNAL ADVANCES 2023. [DOI: 10.1016/j.ceja.2023.100444] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023] Open
|
4
|
Radiometal-theranostics: the first 20 years*. J Radioanal Nucl Chem 2022. [DOI: 10.1007/s10967-022-08624-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
AbstractThis review describes the basic principles of radiometal-theranostics and its dawn based on the development of the positron-emitting 86Y and 86Y-labeled radiopharmaceuticals to quantify biodistribution and dosimetry of 90Y-labeled analogue therapeutics. The nuclear and inorganic development of 86Y (including nuclear and cross section data, irradiation, radiochemical separation and recovery) led to preclinical and clinical evaluation of 86Y-labeled citrate and EDTMP complexes and yielded organ radiation doses in terms of mGy/MBq 90Y. The approach was extended to [86/90Y]Y-DOTA-TOC, yielding again yielded organ radiation doses in terms of mGy/MBq 90Y. The review further discusses the consequences of this early development in terms of further radiometals that were used (68Ga, 177Lu etc.), more chelators that were developed, new biological targets that were addressed (SSTR, PSMA, FAP, etc.) and subsequent generations of radiometal-theranostics that resulted out of that.
Collapse
|
5
|
Zhuo L, Yang Y, Yue H, Xiong X, Wang G, Wang H, Yang L, Lin Q, Chen Q, Tu J, Wei H, Yang X, Kan W. Effective lutetium/ytterbium separation for no-carrier added lutetium-177 production. J Radioanal Nucl Chem 2022. [DOI: 10.1007/s10967-022-08588-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
6
|
Kim A, Choi K. Preparative chromatographic separation of neighboring lanthanides using amines as a pH adjusting additive for producing carrier-free 177Lu. J Radioanal Nucl Chem 2022. [DOI: 10.1007/s10967-022-08216-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
7
|
Cáceres-Rivero C, Ramos-Trujillo BJ, Farfán Y, Solis JL, Bedregal P. The role of pH in the separation of Lu and Yb by ion-exchange explained by novel chemical structures of lanthanide complexes. RESULTS IN CHEMISTRY 2022. [DOI: 10.1016/j.rechem.2022.100514] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022] Open
|
8
|
Müller C, Schibli R, Bernhardt P, Köster U, van der Meulen NP. Terbium radionuclides for theranostics. Nucl Med Mol Imaging 2022. [DOI: 10.1016/b978-0-12-822960-6.00076-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
|
9
|
Radchenko V, Baimukhanova A, Filosofov D. Radiochemical aspects in modern radiopharmaceutical trends: a practical guide. SOLVENT EXTRACTION AND ION EXCHANGE 2021. [DOI: 10.1080/07366299.2021.1874099] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Affiliation(s)
- Valery Radchenko
- Life Sciences Division, TRIUMF, Vancouver, Canada
- Department of Chemistry, University of British Columbia, Vancouver, BC, Canada
| | - Ayagoz Baimukhanova
- Dzelepov Laboratory of Nuclear Problems, Joint Institute for Nuclear Research, Dubna, Russian Federation
- Scientific and Technical Center of Radiochemistry and Isotopes Production, Institute of Nuclear Physics, Almaty, Kazakhstan
| | - Dmitry Filosofov
- Dzelepov Laboratory of Nuclear Problems, Joint Institute for Nuclear Research, Dubna, Russian Federation
| |
Collapse
|
10
|
Vosoughi S, Salek N, Arani SS, Samani AB, Maragheh MG. Investigation of radiolabeling efficacy by enhancement of the chemical form of no carrier added 177Lu isolated by electro amalgamation process. Curr Radiopharm 2021; 15:56-62. [PMID: 33480353 DOI: 10.2174/1874471014666210122150134] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2020] [Revised: 11/30/2020] [Accepted: 12/01/2020] [Indexed: 11/22/2022]
Abstract
BACKGROUND Due to the suitable nuclear decay characteristics, 177Lu is an attractive radionuclide for various therapeutic applications. The non-carrier added form of 177Lu has drawn many attention because of its high specific activity needed in radiolabeling studies. There have been several separation methods for NCA 177Lu production. OBJECTIVES Among the various separation methods, the electro-amalgamation separation method has got a large potential for large scale production. Li presence is a significant problem in this separation method, which seriously affects the radiolabeling efficiency. METHOD In this study, Li was separated from the final product of electro-amalgamation separation by adding an ion-exchange chromatography column to the separation process. RESULTS NCA 177Lu was obtained by 84.09% ELM separation yield, 99.9% radionuclide purity and, 65 Ci/g specific activity. Then, 177Lu (177LuCl3 chemical form) was separated from Li using the ion exchange chromatography method by a separation yield of 94%. The obtained results of the radiolabeling efficacy studies showed that the radiochemical purity and radio-complex stability were significantly increased by separating of NCA 177Lu from Li. CONCLUSION This new separation setup consisting of two steps allows using 177Lu of such a favorable quality for labeling studies.
Collapse
Affiliation(s)
- Sara Vosoughi
- Radiation Application Research School, Nuclear Science and Technology Research Institute (NSTRI),Tehran. Iran
| | - Nafise Salek
- Nuclear Fuel Research School, Nuclear Science and Technology Research Institute (NSTRI). Iran
| | | | - Ali Bahrami Samani
- Nuclear Fuel Research School, Nuclear Science and Technology Research Institute (NSTRI). Iran
| | | |
Collapse
|
11
|
Sinnes JP, Bauder-Wüst U, Schäfer M, Moon ES, Kopka K, Rösch F. 68Ga, 44Sc and 177Lu-labeled AAZTA 5-PSMA-617: synthesis, radiolabeling, stability and cell binding compared to DOTA-PSMA-617 analogues. EJNMMI Radiopharm Chem 2020; 5:28. [PMID: 33242189 PMCID: PMC7691401 DOI: 10.1186/s41181-020-00107-8] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2020] [Accepted: 10/19/2020] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND The AAZTA chelator and in particular its bifunctional derivative AAZTA5 was recently investigated to demonstrate unique capabilities to complex diagnostic and therapeutic trivalent radiometals under mild conditions. This study presents a comparison of 68Ga, 44Sc and 177Lu-labeled AAZTA5-PSMA-617 with DOTA-PSMA-617 analogues. We evaluated the radiolabeling characteristics, in vitro stability of the radiolabeled compounds and evaluated their binding affinity and internalization behavior on LNCaP tumor cells in direct comparison to the radiolabeled DOTA-conjugated PSMA-617 analogs. RESULTS AAZTA5 was synthesized in a five-step synthesis and coupled to the PSMA-617 backbone on solid phase. Radiochemical evaluation of AAZTA5-PSMA-617 with 68Ga, 44Sc and 177Lu achieved quantitative radiolabeling of > 99% after less than 5 min at room temperature. Stabilities against human serum, PBS buffer and EDTA and DTPA solutions were analyzed. While there was a small degradation of the 68Ga complex over 2 h in human serum, PBS and EDTA/DTPA, the 44Sc and 177Lu complexes were stable at 2 h and remained stable over 8 h and 1 day. For all three compounds, i.e. [natGa]Ga-AAZTA5-PSMA-617, [natSc]Sc-AAZTA5-PSMA-617 and [natLu]Lu-AAZTA5-PSMA-617, in vitro studies on PSMA-positive LNCaP cells were performed in direct comparison to radiolabeled DOTA-PSMA-617 yielding the corresponding inhibition constants (Ki). Ki values were in the range of 8-31 nM values which correspond with those of [natGa]Ga-DOTA-PSMA-617, [natSc]Sc-DOTA-PSMA-617 and [natLu]Lu-DOTA-PSMA-617, i.e. 5-7 nM, respectively. Internalization studies demonstrated cellular membrane to internalization ratios for the radiolabeled 68Ga, 44Sc and 177Lu-AAZTA5-PSMA-617 tracers (13-20%IA/106 cells) in the same range as the ones of the three radiolabeled DOTA-PSMA-617 tracers (17-20%IA/106 cells) in the same assay. CONCLUSIONS The AAZTA5-PSMA-617 structure proved fast and quantitative radiolabeling with all three radiometal complexes at room temperature, excellent stability with 44Sc, very high stability with 177Lu and medium stability with 68Ga in human serum, PBS and EDTA/DTPA solutions. All three AAZTA5-PSMA-617 tracers showed binding affinities and internalization ratios in LNCaP cells comparable with that of radiolabeled DOTA-PSMA-617 analogues. Therefore, the exchange of the chelator DOTA with AAZTA5 within the PSMA-617 binding motif has no negative influence on in vitro LNCaP cell binding characteristics. In combination with the faster and milder radiolabeling features, AAZTA5-PSMA-617 thus demonstrates promising potential for in vivo application for theranostics of prostate cancer.
Collapse
Affiliation(s)
- Jean-Philippe Sinnes
- Johannes Gutenberg-University Mainz, Department of Chemistry/ TRIGA, Fritz-Strassmann-Weg 2, 55128, Mainz, Germany
| | - Ulrike Bauder-Wüst
- German Cancer Research Center (DKFZ), Division of Radiopharmaceutical Chemistry, Im Neuenheimer Feld 280, 69120, Heidelberg, Germany
| | - Martin Schäfer
- German Cancer Research Center (DKFZ), Division of Radiopharmaceutical Chemistry, Im Neuenheimer Feld 280, 69120, Heidelberg, Germany
| | - Euy Sung Moon
- Johannes Gutenberg-University Mainz, Department of Chemistry/ TRIGA, Fritz-Strassmann-Weg 2, 55128, Mainz, Germany
| | - Klaus Kopka
- German Cancer Research Center (DKFZ), Division of Radiopharmaceutical Chemistry, Im Neuenheimer Feld 280, 69120, Heidelberg, Germany.,German Cancer Research Center (DKFZ), Division of Radiopharmaceutical Chemistry and German Cancer Consortium (DKTK), Im Neuenheimer Feld 280, 69120, Heidelberg, Germany.,New address: Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Institute of Radiopharmaceutical Cancer Research, Bautzner Landstraße 400, 01328, Dresden, Germany
| | - Frank Rösch
- Johannes Gutenberg-University Mainz, Department of Chemistry/ TRIGA, Fritz-Strassmann-Weg 2, 55128, Mainz, Germany.
| |
Collapse
|
12
|
Yadav MP, Ballal S, Meckel M, Roesch F, Bal C. [ 177Lu]Lu-DOTA-ZOL bone pain palliation in patients with skeletal metastases from various cancers: efficacy and safety results. EJNMMI Res 2020; 10:130. [PMID: 33113035 PMCID: PMC7593375 DOI: 10.1186/s13550-020-00709-y] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2020] [Accepted: 09/21/2020] [Indexed: 12/29/2022] Open
Abstract
Background [177Lu]Lu-DOTA-ZOL has shown promising results from the dosimetry and preclinical aspects, but data on its role in the clinical efficacy are limited. The objective of this study is to evaluate the efficacy and safety of [177Lu]Lu-DOTA-ZOL as a bone pain palliation agent in patients experiencing pain due to skeletal metastases from various cancers. Methods In total, 40 patients experiencing bone pain due to skeletal metastases were enrolled in this study. The patients were treated with a mean cumulative dose of 2.1 ± 0.6 GBq (1.3–2.7 GBq) [177Lu]Lu-DOTA-ZOL in a median follow-up duration of 10 months (IQR 8–14 months). The primary outcome endpoint was response assessment according to the visual analogue score (VAS). Secondary endpoints included analgesic score (AS), global pain assessment score, Eastern Cooperative Oncology Group Assessment performance status (ECOG), Karnofsky performance status, overall survival, and safety assessment by the National Cancer Institute’s Common Toxicity Criteria V5.0. Results In total, 40 patients (15 males and 25 females) with a mean age of 46.6 ± 15.08 years (range 24–78 years) were treated with either 1 (N = 15) or 2 (N = 25) cycles of [177Lu]Lu-DOTA-ZOL. According to the VAS response assessment criteria, complete, partial, and minimal responses were observed in 11 (27.5%), 20 (50%), and 5 patients (12.5%), respectively with an overall response rate of 90%. Global pain assessment criteria revealed complete, partial, minimal, and no response in 2 (5%), 25 (62.5%), 9 (22.5%), and 4 (10%) patients, respectively. Twenty-eight patients died and the estimated median overall survival was 13 months (95% CI 10–14 months). A significant improvement was observed in the VAS, AS, and ECOG status when compared to baseline. None of the patients experienced grade III/IV haematological, kidney, or hepatotoxicity due to [177Lu]Lu-DOTA-ZOL therapy. Conclusion [177Lu]Lu-DOTA-ZOL shows promising results and is an effective radiopharmaceutical in the treatment of bone pain due to skeletal metastases from various cancers.
Collapse
Affiliation(s)
- Madhav Prasad Yadav
- Department of Nuclear Medicine, Room No: 59-A, Thyroid Clinic, All India Institute of Medical Sciences (AIIMS), Ansari Nagar, New Delhi, 110029, India
| | - Sanjana Ballal
- Department of Nuclear Medicine, Room No: 59-A, Thyroid Clinic, All India Institute of Medical Sciences (AIIMS), Ansari Nagar, New Delhi, 110029, India
| | - Marian Meckel
- Department of Nuclear Chemistry, Johannes Gutenberg University, Fritz-Strassmann-Weg 2, 55126, Mainz, Germany
| | - Frank Roesch
- Department of Nuclear Chemistry, Johannes Gutenberg University, Fritz-Strassmann-Weg 2, 55126, Mainz, Germany
| | - Chandrasekhar Bal
- Department of Nuclear Medicine, Room No: 59-A, Thyroid Clinic, All India Institute of Medical Sciences (AIIMS), Ansari Nagar, New Delhi, 110029, India.
| |
Collapse
|
13
|
Bhardwaj R, Wolterbeek HT, Denkova AG, Serra-Crespo P. Modelling of the 177mLu/ 177Lu radionuclide generator. Appl Radiat Isot 2020; 166:109261. [PMID: 32961525 DOI: 10.1016/j.apradiso.2020.109261] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2019] [Revised: 04/24/2020] [Accepted: 06/01/2020] [Indexed: 10/23/2022]
Abstract
In order to determine the potential of 177mLu/177Lu radionuclide generator in 177Lu production it is important to establish the technical needs that can lead to a clinically acceptable 177Lu product quality. In this work, a model that includes all the processes and the parameters affecting the performance of the 177mLu/177Lu radionuclide generator has been developed. The model has been based on the use of a ligand to complex 177mLu ions, followed by the separation of the freed 177Lu ions. The dissociation kinetics of the Lu-ligand complex has been found to be the most crucial aspect governing the specific activity and 177mLu content of the produced 177Lu. The dissociation rate constants lower than 1*10-11 s-1 would be required to lead to onsite 177Lu production with specific activity close to theoretical maximum of 4.1 TBq 177Lu/mg Lu and with 177mLu content of less than 0.01%. Lastly, the calculations suggest that more than one patient dose per week can be supplied for a period of up to 7 months on starting with the 177mLu produced using 3 g Lu2O3 target with 60% 176Lu enrichment. The requirements of the starting 177mLu activity production needs to be adapted depending on the required patient doses, and the technical specifications of the involved 177mLu-177Lu separation process.
Collapse
Affiliation(s)
- Rupali Bhardwaj
- Applied Radiation and Isotopes, Department of Radiation Science and Technology, Faculty of Applied Sciences, Delft University of Technology, Mekelweg 15, 2629 JB, Delft, the Netherlands; Catalysis Engineering, Department of Chemical Engineering, Faculty of Applied Sciences, Delft University of Technology, Van der Maasweg 9, 2629 HZ, Delft, the Netherlands
| | - Hubert T Wolterbeek
- Applied Radiation and Isotopes, Department of Radiation Science and Technology, Faculty of Applied Sciences, Delft University of Technology, Mekelweg 15, 2629 JB, Delft, the Netherlands
| | - Antonia G Denkova
- Applied Radiation and Isotopes, Department of Radiation Science and Technology, Faculty of Applied Sciences, Delft University of Technology, Mekelweg 15, 2629 JB, Delft, the Netherlands
| | - Pablo Serra-Crespo
- Applied Radiation and Isotopes, Department of Radiation Science and Technology, Faculty of Applied Sciences, Delft University of Technology, Mekelweg 15, 2629 JB, Delft, the Netherlands.
| |
Collapse
|
14
|
Basu S, Parghane RV, Kamaldeep, Chakrabarty S. Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors. Semin Nucl Med 2020; 50:447-464. [PMID: 32768008 DOI: 10.1053/j.semnuclmed.2020.05.004] [Citation(s) in RCA: 25] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
Peptide receptor radionuclide therapy (PRRT), over the years, has evolved as an important modality in the therapeutic armamentarium of advanced, metastatic or inoperable, progressive Neuroendocrine Neoplasms (NENs). This review deliberates on the basic understanding and applied clinical aspects of PRRT in NENs, with special reference to (1) tumor biology and receptor characteristics, (2) molecular PET-CT imaging (in particular the invaluable role of dual-tracer PET with [68Ga]-DOTA-TATE/NOC and [18F]-FDG for exploring tumor biology in continuum and individualizing treatment decision making) and NEN theranostics, (3) relevant radiochemistry of different therapeutic radionuclides (both beta emitting 177Lu-DOTATATE and 90Y-DOTATATE and alpha emitting 225Ac-DOTATATE), and (4) related dosimetric considerations. Successful clinical management of the NENs would require multifactorial considerations, and all the aforementioned points pertaining to the disease process and available logistics are key considerations for state-of-the-art clinical practice and delivering personalized care in this group of patients. Emphasis has been placed on relatively intriguing areas such as (1) NET grade 3 of WHO 2017 classification (ie, Ki-67>20% but well-differentiation features), (2) "Neoadjuvant PRRT," (3) combining chemotherapy and PRRT, (4) 'Sandwich Chemo-PRRT', (5) duo-PRRT and tandem PRRT, (6) resistant functioning disease with nuances in clinical management and how one can advocate PRRT rationally in such clinical settings and individualize the management in a patient specific manner. Relevant clinical management issues related to some difficult case scenarios, which the Nuclear Medicine attending physician should be aware of to run an efficient clinical PRRT services, are described.
Collapse
Affiliation(s)
- Sandip Basu
- Radiation Medicine Centre, Bhabha Atomic Research Centre, Tata Memorial Hospital Annexe, Mumbai, India; Homi Bhabha National Institute, Mumbai, India.
| | - Rahul V Parghane
- Radiation Medicine Centre, Bhabha Atomic Research Centre, Tata Memorial Hospital Annexe, Mumbai, India; Homi Bhabha National Institute, Mumbai, India
| | - Kamaldeep
- Homi Bhabha National Institute, Mumbai, India; Health Physics Division, Bhabha Atomic Research Centre Mumbai, India
| | - Sudipta Chakrabarty
- Homi Bhabha National Institute, Mumbai, India; Radiochemicals Section, Radiopharmaceuticals Division, Bhabha Atomic Research Centre Mumbai, India
| |
Collapse
|
15
|
Baranyai Z, Tircsó G, Rösch F. The Use of the Macrocyclic Chelator DOTA in Radiochemical Separations. Eur J Inorg Chem 2019. [DOI: 10.1002/ejic.201900706] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Affiliation(s)
- Zsolt Baranyai
- Bracco Research Centre Bracco Imaging spa Via Ribes 5 10010 Colleretto Giacosa (TO) Italy
| | - Gyula Tircsó
- Department of Physical Chemistry Faculty of Science and Technology University of Debrecen Egyetem tér 1 Debrecen 4032 Hungary
| | - Frank Rösch
- Institute of Nuclear Chemistry Johannes Gutenberg‐University of Mainz Fritz‐Strassmann‐Weg 2 55128 Mainz Germany
| |
Collapse
|
16
|
Kuznetsov RA, Bobrovskaya KS, Svetukhin VV, Fomin AN, Zhukov AV. Production of Lutetium-177: Process Aspects. RADIOCHEMISTRY 2019. [DOI: 10.1134/s1066362219040015] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
17
|
Greifenstein L, Grus T, Nagel J, Sinnes JP, Rösch F. Synthesis and labeling of a squaric acid containing PSMA-inhibitor coupled to AAZTA 5 for versatile labeling with 44Sc, 64Cu, 68Ga and 177Lu. Appl Radiat Isot 2019; 156:108867. [PMID: 31883763 DOI: 10.1016/j.apradiso.2019.108867] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2019] [Revised: 07/25/2019] [Accepted: 08/14/2019] [Indexed: 01/02/2023]
Affiliation(s)
- Lukas Greifenstein
- Institute of Nuclear Chemistry, Johannes Gutenberg University, Mainz, Germany, Fritz-Strassmann-Weg 2, 55128, Mainz
| | - Tilmann Grus
- Institute of Nuclear Chemistry, Johannes Gutenberg University, Mainz, Germany, Fritz-Strassmann-Weg 2, 55128, Mainz
| | - Johannes Nagel
- Institute of Nuclear Chemistry, Johannes Gutenberg University, Mainz, Germany, Fritz-Strassmann-Weg 2, 55128, Mainz
| | - Jean Phillip Sinnes
- Institute of Nuclear Chemistry, Johannes Gutenberg University, Mainz, Germany, Fritz-Strassmann-Weg 2, 55128, Mainz
| | - Frank Rösch
- Institute of Nuclear Chemistry, Johannes Gutenberg University, Mainz, Germany, Fritz-Strassmann-Weg 2, 55128, Mainz.
| |
Collapse
|
18
|
Sinnes JP, Nagel J, Rösch F. AAZTA 5/AAZTA 5-TOC: synthesis and radiochemical evaluation with 68Ga, 44Sc and 177Lu. EJNMMI Radiopharm Chem 2019; 4:18. [PMID: 31659525 PMCID: PMC6675801 DOI: 10.1186/s41181-019-0068-1] [Citation(s) in RCA: 25] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2018] [Accepted: 07/16/2019] [Indexed: 11/10/2022] Open
Abstract
PURPOSE AAZTA (1,4-bis (carboxymethyl)-6-[bis (carboxymethyl)]amino-6-methylperhydro-1,4-diazepine) based chelators were initially developed in the context of magnetic resonance imaging. First radiochemical studies showed the capability of AAZTA to form stable complexes with radiolanthanides and moderately stable complexes with 68Ga. For a systematic comparison of the labelling capabilities with current diagnostic and therapeutic trivalent radiometals, AAZTA5 (1,4-bis (carboxymethyl)-6-[bis (carboxymethyl)]amino-6-[pentanoic-acid]perhydro-1,4-diazepine) was synthesized representing a bifunctional version with a pentanoic acid at the carbon-6 atom. To evaluate the effect of adding a targeting vector (TV) to the bifunctional chelator on the complex formation, AAZTA5-TOC was synthesized, radiolabeled and tested in comparison to the uncoupled AAZTA5. METHODS AAZTA5 was synthesized in a 5-step synthesis. It was coupled to the cyclic peptide TOC (Phe1-Tyr3 octreotide) via amide bound formation. AAZTA and AAZTA5-TOC complex formations with 68Ga, 44Sc and 177Lu were investigated at different pH, temperature and precursor amounts. Stability studies against human serum, PBS buffer, EDTA and DTPA were performed. RESULTS AAZTA5 and AAZTA5-TOC achieved quantitative labelling (> 95%) at room temperature in less than 5 min with all three nuclides at pH ranges from 4 to 5.5 with low precursor amounts of 1 to 10 nmol. [44Sc]Sc-AAZTA5 complexes as well as [44Sc]Sc-AAZTA5-TOC were completely stable. The 177Lu complexes of AAZTA5 and AAZTA5-TOC showed high stability comparable to the 44Sc complexes. In contrast, the [68Ga]Ga-AAZTA5 complex stability was rather low, but interestingly, [68Ga]Ga-AAZTA5-TOC was completely stable. CONCLUSION AAZTA5 appears to be a promising bifunctional chelator for 68Ga, 44Sc and 177Lu with outstanding labelling capabilities at room temperature. Complex stabilities are high in the case of 44Sc and 177Lu. While [68Ga]Ga-AAZTA complexes alone lacking stability, [68Ga]Ga-AAZTA5-TOC demonstrated high stability. The latter indicates an interesting feature of [68Ga]Ga-AAZTA5-labelled radiopharmaceuticals.
Collapse
Affiliation(s)
- Jean-Philippe Sinnes
- Johannes Gutenberg-University Mainz, Institute of Nuclear Chemistry, Fritz-Strassmann-Weg 2, 55128, Mainz, Germany
| | - Johannes Nagel
- Johannes Gutenberg-University Mainz, Institute of Nuclear Chemistry, Fritz-Strassmann-Weg 2, 55128, Mainz, Germany
| | - Frank Rösch
- Johannes Gutenberg-University Mainz, Institute of Nuclear Chemistry, Fritz-Strassmann-Weg 2, 55128, Mainz, Germany.
| |
Collapse
|
19
|
Mikolajczak R, van der Meulen NP, Lapi SE. Radiometals for imaging and theranostics, current production, and future perspectives. J Labelled Comp Radiopharm 2019; 62:615-634. [PMID: 31137083 DOI: 10.1002/jlcr.3770] [Citation(s) in RCA: 35] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/18/2018] [Revised: 04/10/2019] [Accepted: 05/15/2019] [Indexed: 02/06/2023]
Abstract
The aim of this review is to make the reader familiar with currently available radiometals, their production modes, capacities, and quality concerns related to their medical use, as well as new emerging radiometals and irradiation technologies from the perspective of their diagnostic and theranostic applications. Production methods of 177 Lu serve as an example of various issues related to the production yield, specific activity, radionuclidic and chemical purity, and production economy. Other radiometals that are currently used or explored for potential medical applications, with particular focus on their theranostic value, are discussed. Using radiometals for diagnostic imaging and therapy is on the rise. The high demand for radiometals for medical use prompts investigations towards using alternative irradiation reactions, while using existing nuclear reactors and accelerator facilities. This review discusses these production capacities and what is necessary to cover the growing demand for theranostic nuclides.
Collapse
Affiliation(s)
- Renata Mikolajczak
- Radioisotope Centre POLATOM, National Centre for Nuclear Research, Otwock, Poland
| | | | - Suzanne E Lapi
- Department of Radiology, University of Alabama at Birmingham, Birmingham, Alabama
| |
Collapse
|
20
|
Radiochemical processing of nuclear-reactor-produced radiolanthanides for medical applications. Coord Chem Rev 2019. [DOI: 10.1016/j.ccr.2018.11.007] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
|
21
|
Abstract
Radiometals possess an exceptional breadth of decay properties and have been applied to medicine with great success for several decades. The majority of current clinical use involves diagnostic procedures, which use either positron-emission tomography (PET) or single-photon imaging to detect anatomic abnormalities that are difficult to visualize using conventional imaging techniques (e.g., MRI and X-ray). The potential of therapeutic radiometals has more recently been realized and relies on ionizing radiation to induce irreversible DNA damage, resulting in cell death. In both cases, radiopharmaceutical development has been largely geared toward the field of oncology; thus, selective tumor targeting is often essential for efficacious drug use. To this end, the rational design of four-component radiopharmaceuticals has become popularized. This Review introduces fundamental concepts of drug design and applications, with particular emphasis on bifunctional chelators (BFCs), which ensure secure consolidation of the radiometal and targeting vector and are integral for optimal drug performance. Also presented are detailed accounts of production, chelation chemistry, and biological use of selected main group and rare earth radiometals.
Collapse
Affiliation(s)
- Thomas I Kostelnik
- Medicinal Inorganic Chemistry Group, Department of Chemistry , University of British Columbia , Vancouver , British Columbia V6T 1Z1 , Canada
| | - Chris Orvig
- Medicinal Inorganic Chemistry Group, Department of Chemistry , University of British Columbia , Vancouver , British Columbia V6T 1Z1 , Canada
| |
Collapse
|
22
|
Feasibility study for production and quality control of Yb-175 as a byproduct of no carrier added Lu-177 preparation for radiolabeling of DOTMP. AUSTRALASIAN PHYSICAL & ENGINEERING SCIENCES IN MEDICINE 2017; 41:69-79. [PMID: 29260406 DOI: 10.1007/s13246-017-0611-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/30/2016] [Accepted: 12/11/2017] [Indexed: 10/18/2022]
Abstract
Skeletal uptake of β- emitters of DOTMP complexes is used for the bone pain palliation. In this study, two moderate energy β- emitters, 177Lu (T1/2 = 6.7 days, Eβmax = 497 keV) and 175Yb (T1/2 = 4.2 days, Eβmax = 480 keV), are considered as potential agents for the development of the bone-seeking radiopharmaceuticals. Since the specific activity of the radiolabelled carrier molecules should be high, the non-carrier-added (NCA) radionuclides have an effective role in nuclear medicine. Many researchers have presented the synthesis of NCA 177Lu. Among these separation techniques, extraction chromatography has been considered more capable than other methods. In this study, a new approach, in addition to production of NCA 177Lu by EXC procedure is using pure 175Yb that was usually considered as a waste material in this method but because of high radionuclidic purity of 175Yb produced by this method we used it for radiolabeling as well as NCA 177Lu. To obtain optimum conditions, some effective factors on separation of Lu/Yb by EXC were investigated. The NCA 177Lu and pure 175Yb were produced with radionuclidic purity of 99.99 and 99.97% respectively by irradiation of enriched 176Yb target in thermal neutron flux of 5 × 1013 n/cm2 s for 14 days. 177Lu-DOTMP and 175Yb-DOTMP were obtained with high radiochemical purities (> 95%) under optimized reaction conditions. Two radiolabeled complexes exhibited excellent stability at room temperature. Biodistribution studies in rats showed favorable selective skeletal uptake with rapid clearance from blood along with insignificant accumulation of activity in other non-target organs for two radiolabelled complexes.
Collapse
|
23
|
Müller C, van der Meulen NP, Benešová M, Schibli R. Therapeutic Radiometals Beyond 177Lu and 90Y: Production and Application of Promising α-Particle, β−-Particle, and Auger Electron Emitters. J Nucl Med 2017; 58:91S-96S. [DOI: 10.2967/jnumed.116.186825] [Citation(s) in RCA: 47] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2017] [Accepted: 03/13/2017] [Indexed: 12/31/2022] Open
|
24
|
Pfannkuchen N, Meckel M, Bergmann R, Bachmann M, Bal C, Sathekge M, Mohnike W, Baum RP, Rösch F. Novel Radiolabeled Bisphosphonates for PET Diagnosis and Endoradiotherapy of Bone Metastases. Pharmaceuticals (Basel) 2017; 10:ph10020045. [PMID: 28524118 PMCID: PMC5490402 DOI: 10.3390/ph10020045] [Citation(s) in RCA: 41] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2017] [Revised: 05/03/2017] [Accepted: 05/05/2017] [Indexed: 01/25/2023] Open
Abstract
Bone metastases, often a consequence of breast, prostate, and lung carcinomas, are characterized by an increased bone turnover, which can be visualized by positron emission tomography (PET), as well as single-photon emission computed tomography (SPECT). Bisphosphonate complexes of 99mTc are predominantly used as SPECT tracers. In contrast to SPECT, PET offers a higher spatial resolution and, owing to the 68Ge/68Ga generator, an analog to the established 99mTc generator exists. Complexation of Ga(III) requires the use of chelators. Therefore, DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid), NOTA (1,4,7-triazacyclododecane-1,4,7-triacetic acid), and their derivatives, are often used. The combination of these macrocyclic chelators and bisphosphonates is currently studied worldwide. The use of DOTA offers the possibility of a therapeutic application by complexing the β-emitter 177Lu. This overview describes the possibility of diagnosing bone metastases using [68Ga]Ga-BPAMD (68Ga-labeled (4-{[bis-(phosphonomethyl))carbamoyl]methyl}-7,10-bis(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl)acetic acid) as well as the successful application of [177Lu]Lu-BPAMD for therapy and the development of new diagnostic and therapeutic tools based on this structure. Improvements concerning both the chelator and the bisphosphonate structure are illustrated providing new 68Ga- and 177Lu-labeled bisphosphonates offering improved pharmacological properties.
Collapse
Affiliation(s)
- Nina Pfannkuchen
- Institute of Nuclear Chemistry, Johannes Gutenberg University Mainz, Fritz-Strassmann-Weg 2, 55128 Mainz, Germany.
| | - Marian Meckel
- Institute of Nuclear Chemistry, Johannes Gutenberg University Mainz, Fritz-Strassmann-Weg 2, 55128 Mainz, Germany.
| | - Ralf Bergmann
- Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Bautzner Landstrasse 400, 01328 Dresden, Germany.
| | - Michael Bachmann
- Helmholtz-Zentrum Dresden-Rossendorf, Institute of Radiopharmaceutical Cancer Research, Bautzner Landstrasse 400, 01328 Dresden, Germany.
- University Cancer Center (UCC) Carl Gustav Carus, Tumorimmunology, Technical University Dresden, Fetscherstr. 74, 01307 Dresden, Germany.
| | - Chandrasekhar Bal
- Department of Nuclear Medicine & PET, All India Institute of Medical Sciences, Ansari Nagar, New Delhi 110029, India.
| | - Mike Sathekge
- Department of Nuclear Medicine, University of Pretoria & Steve Biko Academic Hospital, Private Bag X169, Pretoria 0001, South Africa.
| | - Wolfgang Mohnike
- Diagnostisch Therapeutisches Zentrum, DTZ am Frankfurter Tor, Kadiner Straße 23, 10243 Berlin, Germany.
| | - Richard P Baum
- Department of Nuclear Medicine, Center for PET/CT, Zentralklinik Bad Berka, Robert-Koch-Allee 9, 99438 Bad Berka, Germany.
| | - Frank Rösch
- Institute of Nuclear Chemistry, Johannes Gutenberg University Mainz, Fritz-Strassmann-Weg 2, 55128 Mainz, Germany.
| |
Collapse
|
25
|
Bhardwaj R, van der Meer A, Das SK, de Bruin M, Gascon J, Wolterbeek HT, Denkova AG, Serra-Crespo P. Separation of nuclear isomers for cancer therapeutic radionuclides based on nuclear decay after-effects. Sci Rep 2017; 7:44242. [PMID: 28287131 PMCID: PMC5347157 DOI: 10.1038/srep44242] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2016] [Accepted: 02/06/2017] [Indexed: 11/09/2022] Open
Abstract
177Lu has sprung as a promising radionuclide for targeted therapy. The low soft tissue penetration of its β- emission results in very efficient energy deposition in small-size tumours. Because of this, 177Lu is used in the treatment of neuroendocrine tumours and is also clinically approved for prostate cancer therapy. In this work, we report a separation method that achieves the challenging separation of the physically and chemically identical nuclear isomers, 177mLu and 177Lu. The separation method combines the nuclear after-effects of the nuclear decay, the use of a very stable chemical complex and a chromatographic separation. Based on this separation concept, a new type of radionuclide generator has been devised, in which the parent and the daughter radionuclides are the same elements. The 177mLu/177Lu radionuclide generator provides a new production route for the therapeutic radionuclide 177Lu and can bring significant growth in the research and development of 177Lu based pharmaceuticals.
Collapse
Affiliation(s)
- R Bhardwaj
- Radiation and Isotopes for Health, Department of Radiation Science and Technology, Faculty of Applied Sciences, Technical University Delft, Mekelweg 15, 2629 JB, Delft, The Netherlands.,Catalysis Engineering, Department of Chemical Engineering, Faculty of Applied Sciences, Delft University of Technology, Van der Maasweg 9, 2629 HZ, Delft, The Netherlands
| | - A van der Meer
- Radiation and Isotopes for Health, Department of Radiation Science and Technology, Faculty of Applied Sciences, Technical University Delft, Mekelweg 15, 2629 JB, Delft, The Netherlands
| | - S K Das
- Radiation and Isotopes for Health, Department of Radiation Science and Technology, Faculty of Applied Sciences, Technical University Delft, Mekelweg 15, 2629 JB, Delft, The Netherlands
| | - M de Bruin
- Radiation and Isotopes for Health, Department of Radiation Science and Technology, Faculty of Applied Sciences, Technical University Delft, Mekelweg 15, 2629 JB, Delft, The Netherlands
| | - J Gascon
- Catalysis Engineering, Department of Chemical Engineering, Faculty of Applied Sciences, Delft University of Technology, Van der Maasweg 9, 2629 HZ, Delft, The Netherlands
| | - H T Wolterbeek
- Radiation and Isotopes for Health, Department of Radiation Science and Technology, Faculty of Applied Sciences, Technical University Delft, Mekelweg 15, 2629 JB, Delft, The Netherlands
| | - A G Denkova
- Radiation and Isotopes for Health, Department of Radiation Science and Technology, Faculty of Applied Sciences, Technical University Delft, Mekelweg 15, 2629 JB, Delft, The Netherlands
| | - P Serra-Crespo
- Radiation and Isotopes for Health, Department of Radiation Science and Technology, Faculty of Applied Sciences, Technical University Delft, Mekelweg 15, 2629 JB, Delft, The Netherlands
| |
Collapse
|
26
|
Boldyrev PP, Zagryadskii VA, Erak DY, Kurochkin AV, Markovskii DV, Mikhin OV, Proshin MA, Khmyzov NV, Chuvilin DY, Yashin YA. Possibility of Obtaining High-Activity 177Lu in the IR-8 Research Reactor. ATOM ENERGY+ 2017. [DOI: 10.1007/s10512-017-0185-4] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
27
|
Salek N, Shamsaei M, Ghannadi Maragheh M, Shirvani Arani S, Bahrami Samani A. Production and quality control 177Lu (NCA)-DOTMP as a potential agent for bone pain palliation. J Appl Clin Med Phys 2016; 17:128-139. [PMID: 27929488 PMCID: PMC5690526 DOI: 10.1120/jacmp.v17i6.6375] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2016] [Revised: 07/23/2016] [Accepted: 07/18/2016] [Indexed: 11/23/2022] Open
Abstract
Skeletal uptake of radiolabeled-1, 4, 7, 10-tetraazacyclododecane-1, 4, 7, 10-tetramethylene phosphoric acid (e.g., 177Lu-DOTMP) complex, is used for bone pain palliation. The moderate energy of β-emitting 177Lu (T½ = 6.7 d, Eβmax = 497keV) has been considered as a potential radionuclide for development of the bone-seeking radiopharmaceutical. Since the specific activity of the radiolabeled carrier molecules should be high, the "no-carrier-added radionuclides" have sig-nificant roles in nuclear medicine. Many researchers illustrated no-carrier-added 177Lu production; among these separation techniques such as ion exchange chromatography, reversed phase ion-pair, and electrochemical method, extraction chromatography has been considered more capable than other methods. In order to optimize the conditions, some effective factors on separation of Lu/Yb were investigated by EXC. The NCA 177Lu, produced by this method, was mixed with 300 μl of DOTMP solution (20 mg in 1 mL of 0.5 M NaHCO3, pH = 8) and incu-bated under stirring at room temperature for 45 min. Radiochemical purity of the 177Lu-DOTMP complex was determined using radio-thin-layer chromatography (RTLC) method. The complex was injected to wild-type rats and biodistribution was then studied for seven days. The NCA 177Lu was produced with specific activ-ity of 48 Ci/mg and with a radinuclidic purity of 99.99% through irradiation of enriched 176Yb target (1 mg) in a thermal neutron flux of 4 × 1013 n.cm-2.s-1 for 14 days. 177Lu-DOTMP was obtained with high radiochemical purities (> 98%) under optimized reaction conditions. The radiolabeled complex exhibited excellent stability at room temperature. Biodistribution of the radiolabeled complex studies in rats showed favorable selective skeletal uptake with rapid clearance from blood along with insignificant accumulation within the other nontargeted organs.
Collapse
|
28
|
Qaim SM. Nuclear data for production and medical application of radionuclides: Present status and future needs. Nucl Med Biol 2016; 44:31-49. [PMID: 27821344 DOI: 10.1016/j.nucmedbio.2016.08.016] [Citation(s) in RCA: 107] [Impact Index Per Article: 13.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2016] [Revised: 08/22/2016] [Accepted: 08/23/2016] [Indexed: 11/30/2022]
Abstract
INTRODUCTION The significance of nuclear data in the choice and medical application of a radionuclide is considered: the decay data determine its suitability for organ imaging or internal therapy and the reaction cross section data allow optimisation of its production route. A brief discussion of reaction cross sections and yields is given. STANDARD RADIONUCLIDES The standard SPECT, PET and therapeutic radionuclides are enumerated and their decay and production data are considered. The status of nuclear data is generally good. Some existing discrepancies are outlined. A few promising alternative production routes of 99mTc and 68Ga are discussed. RESEARCH-ORIENTED RADIONUCLIDES The increasing significance of non-standard positron emitters in organ imaging and of low-energy highly-ionizing radiation emitters in internal therapy is discussed, their nuclear data are considered and a brief review of their status is presented. Some other related nuclear data issues are also mentioned. PRODUCTION OF RADIONUCLIDES USING NEWER TECHNOLOGIES The data needs arising from new directions in radionuclide applications (multimode imaging, theranostic approach, radionanoparticles, etc.) are considered. The future needs of data associated with possible utilization of newer irradiation technologies (intermediate energy cyclotron, high-intensity photon accelerator, spallation neutron source, etc.) are outlined. CONCLUSION Except for a few small discrepancies, the available nuclear data are sufficient for routine production and application of radionuclides. Considerable data needs exist for developing novel radionuclides for applications. The developing future technologies for radionuclide production will demand further data-related activities.
Collapse
Affiliation(s)
- Syed M Qaim
- Institut für Neurowissenschaften und Medizin, INM-5 (Nuklearchemie), Forschungszentrum Jülich, D-52425 Jülich, Germany.
| |
Collapse
|
29
|
Lu-177 preparation for radiotherapy application. Appl Radiat Isot 2016; 115:8-12. [DOI: 10.1016/j.apradiso.2016.05.028] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2015] [Revised: 05/24/2016] [Accepted: 05/25/2016] [Indexed: 11/20/2022]
|
30
|
Boldyrev PP, Kurochkin AV, Proshin MA, Chuvilin DY, Yashin YA. A modified electrochemical procedure for isolating 177Lu radionuclide. RADIOCHEMISTRY 2016. [DOI: 10.1134/s106636221605009x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
31
|
Qaim SM, Spahn I, Scholten B, Neumaier B. Uses of alpha particles, especially in nuclear reaction studies and medical radionuclide production. RADIOCHIM ACTA 2016. [DOI: 10.1515/ract-2015-2566] [Citation(s) in RCA: 37] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Abstract
Alpha particles exhibit three important characteristics: scattering, ionisation and activation. This article briefly discusses those properties and outlines their major applications. Among others, α-particles are used in elemental analysis, investigation and improvement of materials properties, nuclear reaction studies and medical radionuclide production. The latter two topics, dealing with activation of target materials, are treated in some detail in this paper. Measurements of excitation functions of α-particle induced reactions shed some light on their reaction mechanisms, and studies of isomeric cross sections reveal the probability of population of high-spin nuclear levels. Regarding medical radionuclides, an overview is presented of the isotopes commonly produced using α-particle beams. Consideration is also given to some routes which could be potentially useful for production of a few other radionuclides. The significance of α-particle induced reactions to produce a few high-spin isomeric states, decaying by emission of low-energy conversion or Auger electrons, which are of interest in localized internal radiotherapy, is outlined. The α-particle beam, thus broadens the scope of nuclear chemistry research related to development of non-standard positron emitters and therapeutic radionuclides.
Collapse
Affiliation(s)
- Syed M. Qaim
- Institut für Neurowissenschaften und Medizin, INM-5: Nuklearchemie, Forschungszentrum Jülich, D-52425 Jülich, Germany
| | - Ingo Spahn
- Institut für Neurowissenschaften und Medizin, INM-5: Nuklearchemie, Forschungszentrum Jülich, D-52425 Jülich, Germany
| | - Bernhard Scholten
- Institut für Neurowissenschaften und Medizin, INM-5: Nuklearchemie, Forschungszentrum Jülich, D-52425 Jülich, Germany
| | - Bernd Neumaier
- Institut für Neurowissenschaften und Medizin, INM-5: Nuklearchemie, Forschungszentrum Jülich, D-52425 Jülich, Germany
| |
Collapse
|
32
|
Bergmann R, Meckel M, Kubíček V, Pietzsch J, Steinbach J, Hermann P, Rösch F. (177)Lu-labelled macrocyclic bisphosphonates for targeting bone metastasis in cancer treatment. EJNMMI Res 2016; 6:5. [PMID: 26780082 PMCID: PMC4715021 DOI: 10.1186/s13550-016-0161-3] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2015] [Accepted: 01/05/2016] [Indexed: 11/24/2022] Open
Abstract
Background Metastatic bone lesion is a common syndrome of many cancer diseases in an advanced state. The major symptom is severe pain, spinal cord compression, and pathological fracture, associated with an obvious morbidity. Common treatments including systemic application of bisphosphonate drugs aim on pain reduction and on improving the quality of life of the patient. Particularly, patients with multiple metastatic lesions benefit from bone-targeting therapeutic radiopharmaceuticals. Agents utilizing beta-emitting radionuclides in routine clinical praxis are, for example, [89Sr]SrCl2 and [153Sm]Sm-EDTMP. No-carrier-added (n.c.a.) 177Lu is remarkably suitable for an application in this scope. Methods Five 1,4,7,10-tetraazacyclododecane N,N′,N′′,N′′-tetra-acetic acid (DOTA)- and DO2A-based bisphosphonates, including monomeric and dimeric structures and one 1,4,7-triazacyclononane-1,4-diacetic acid (NO2A) derivative, were synthesized and labelled with n.c.a. 177Lu. Radio-TLC and high-performance liquid chromatography (HPLC) methods were successfully established for determining radiochemical yields and for quality control. Their binding to hydroxyapatite was measured in vitro. Ex vivo biodistribution experiments and dynamic in vivo single photon computed tomography (SPECT)/CT measurements were performed in healthy rats for 5 min and 1 h periods. Data on %ID/g or standard uptake value (SUV) for femur, blood, and soft-tissue organs were analyzed and compared with [177Lu]citrate. Results Radiolabelling yields for [177Lu]Lu-DOTA and [177Lu]Lu-NO2A monomeric bisphosphonate complexes were >98 % within 15 min. The dimeric macrocyclic bisphosphonates showed a decelerated labelling kinetics, reaching a plateau after 30 min of 60 to 90 % radiolabelling yields. All 177Lu-bisphosphonate complexes showed exclusive accumulation in the skeleton. Blood clearance and renal elimination were fast. SUV data (all for 1 h p.i.) in the femur ranged from 3.34 to 5.67. The bone/blood ratios were between 3.6 and 135.6, correspondingly. 177Lu-bisphosphonate dimers showed a slightly higher bone accumulation (SUVfemur = 4.48 ± 0.38 for [177Lu]Lu-DO2A(PBP)2; SUVfemur = 5.41 ± 0.46 for [177Lu]Lu-DOTA(MBP)2) but a slower blood clearance (SUVblood = 1.25 ± 0.09 for [177Lu]Lu-DO2A(PBP)2; SUVblood = 1.43 ± 0.32 for [177Lu]Lu-DOTA(MBP)2). Conclusions Lu-complexes of macrocyclic bisphosphonates might become options for the therapy of skeletal metastases in the near future, since they show high uptake in bone together with a very low soft-tissue accumulation.
Collapse
Affiliation(s)
- Ralf Bergmann
- Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany
| | - Marian Meckel
- Institute of Nuclear Chemistry, Johannes Gutenberg University of Mainz, Fritz-Strassmann-Weg 2, 55128, Mainz, Germany
| | - Vojtěch Kubíček
- Faculty of Science, Department of Inorganic Chemistry, Charles University Prague, Prague, Czech Republic
| | - Jens Pietzsch
- Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany
| | - Jörg Steinbach
- Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf, Dresden, Germany
| | - Petr Hermann
- Faculty of Science, Department of Inorganic Chemistry, Charles University Prague, Prague, Czech Republic
| | - Frank Rösch
- Institute of Nuclear Chemistry, Johannes Gutenberg University of Mainz, Fritz-Strassmann-Weg 2, 55128, Mainz, Germany.
| |
Collapse
|
33
|
Banerjee S, Pillai MRA, Knapp FFR. Lutetium-177 therapeutic radiopharmaceuticals: linking chemistry, radiochemistry, and practical applications. Chem Rev 2015; 115:2934-74. [PMID: 25865818 DOI: 10.1021/cr500171e] [Citation(s) in RCA: 157] [Impact Index Per Article: 17.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Affiliation(s)
- Sharmila Banerjee
- Radiopharmaceuticals Chemistry Section, Bhabha Atomic Research Centre (BARC), Mumbai 400 085, India.,Molecular Group of Companies, Puthuvype, Ernakulam, Kerala 682 508, India.,Medical Radioisotope Program, Oak Ridge National Laboratory (ORNL), P.O. Box 2008, 1 Bethel Valley Road, Oak Ridge, Tennessee 37830-6229, United States
| | - M R A Pillai
- Radiopharmaceuticals Chemistry Section, Bhabha Atomic Research Centre (BARC), Mumbai 400 085, India.,Molecular Group of Companies, Puthuvype, Ernakulam, Kerala 682 508, India.,Medical Radioisotope Program, Oak Ridge National Laboratory (ORNL), P.O. Box 2008, 1 Bethel Valley Road, Oak Ridge, Tennessee 37830-6229, United States
| | - F F Russ Knapp
- Radiopharmaceuticals Chemistry Section, Bhabha Atomic Research Centre (BARC), Mumbai 400 085, India.,Molecular Group of Companies, Puthuvype, Ernakulam, Kerala 682 508, India.,Medical Radioisotope Program, Oak Ridge National Laboratory (ORNL), P.O. Box 2008, 1 Bethel Valley Road, Oak Ridge, Tennessee 37830-6229, United States
| |
Collapse
|
34
|
Meckel M, Nauth A, Timpe J, Zhernosekov K, Puranik AD, Baum RP, Rösch F. Development of a [177Lu]BPAMD labeling kit and an automated synthesis module for routine bone targeted endoradiotherapy. Cancer Biother Radiopharm 2015; 30:94-9. [PMID: 25714451 DOI: 10.1089/cbr.2014.1720] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023] Open
Abstract
Painful bone lesions, both benign and metastatic, are often managed using conventional analgesics. However, the treatment response is not immediate and is often associated with side-effects. Radionuclide therapy is used for pain palliation in bone metastases as well as some benign neoplasms. Endoradiotherapy has direct impact on the pain-producing bone elements, and hence, response is significant, with minimal or no side-effects. A new potential compound for endoradiotherapy is [(177)Lu]BPAMD. It combines a highly affine bisphosphonate, covalently bridged with DOTA through an amide bond, with the low-energy β(-) emitting therapeutic radiolanthanide (177)Lu. For routine chemical application, an automated synthesis of this radiopharmaceutical and a Kit-type labeling procedure appears to be a basic requirement for its good manufacturing practice (GMP) based production. A Kit formulation combining BPAMD, acetate buffer, and ethanol resulted in almost quantitative labeling yields. The use of ethanol and ascorbic acid as quenchers prevented radiolysis over 48 hours. An automated synthesis unit was designed for the production of therapeutic doses of [(177)Lu]BPAMD up to 5 GBq. The procedure was successfully applied for patient treatments.
Collapse
Affiliation(s)
- Marian Meckel
- 1 Institute of Nuclear Chemistry, Johannes Gutenberg University of Mainz , Mainz, Germany
| | | | | | | | | | | | | |
Collapse
|
35
|
Dash A, Chakraborty S, Pillai MRA, Knapp FFR. Peptide receptor radionuclide therapy: an overview. Cancer Biother Radiopharm 2015; 30:47-71. [PMID: 25710506 DOI: 10.1089/cbr.2014.1741] [Citation(s) in RCA: 77] [Impact Index Per Article: 8.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023] Open
Abstract
Peptide receptor radionuclide therapy (PRRT) is a site-directed targeted therapeutic strategy that specifically uses radiolabeled peptides as biological targeting vectors designed to deliver cytotoxic levels of radiation dose to cancer cells, which overexpress specific receptors. Interest in PRRT has steadily grown because of the advantages of targeting cellular receptors in vivo with high sensitivity as well as specificity and treatment at the molecular level. Recent advances in molecular biology have not only stimulated advances in PRRT in a sustainable manner but have also pushed the field significantly forward to several unexplored possibilities. Recent decades have witnessed unprecedented endeavors for developing radiolabeled receptor-binding somatostatin analogs for the treatment of neuroendocrine tumors, which have played an important role in the evolution of PRRT and paved the way for the development of other receptor-targeting peptides. Several peptides targeting a variety of receptors have been identified, demonstrating their potential to catalyze breakthroughs in PRRT. In this review, the authors discuss several of these peptides and their analogs with regard to their applications and potential in radionuclide therapy. The advancement in the availability of combinatorial peptide libraries for peptide designing and screening provides the capability of regulating immunogenicity and chemical manipulability. Moreover, the availability of a wide range of bifunctional chelating agents opens up the scope of convenient radiolabeling. For these reasons, it would be possible to envision a future where the scope of PRRT can be tailored for patient-specific application. While PRRT lies at the interface between many disciplines, this technology is inextricably linked to the availability of the therapeutic radionuclides of required quality and activity levels and hence their production is also reviewed.
Collapse
Affiliation(s)
- Ashutosh Dash
- 1 Isotope Production and Applications Division, Bhabha Atomic Research Centre , Mumbai, India
| | | | | | | |
Collapse
|
36
|
Dash A, Pillai MRA, Knapp FF. Production of (177)Lu for Targeted Radionuclide Therapy: Available Options. Nucl Med Mol Imaging 2015; 49:85-107. [PMID: 26085854 DOI: 10.1007/s13139-014-0315-z] [Citation(s) in RCA: 141] [Impact Index Per Article: 15.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2014] [Revised: 12/20/2014] [Accepted: 12/23/2014] [Indexed: 10/24/2022] Open
Abstract
BACKGROUND This review provides a comprehensive summary of the production of (177)Lu to meet expected future research and clinical demands. Availability of options represents the cornerstone for sustainable growth for the routine production of adequate activity levels of (177)Lu having the required quality for preparation of a variety of (177)Lu-labeled radiopharmaceuticals. The tremendous prospects associated with production of (177)Lu for use in targeted radionuclide therapy (TRT) dictate that a holistic consideration should evaluate all governing factors that determine its success. METHODS While both "direct" and "indirect" reactor production routes offer the possibility for sustainable (177)Lu availability, there are several issues and challenges that must be considered to realize the full potential of these production strategies. RESULTS This article presents a mini review on the latest developments, current status, key challenges and possibilities for the near future. CONCLUSION A broad understanding and discussion of the issues associated with (177)Lu production and processing approaches would not only ensure sustained growth and future expansion for the availability and use of (177)Lu-labeled radiopharmaceuticals, but also help future developments.
Collapse
Affiliation(s)
- Ashutosh Dash
- Isotope Production and Applications Division, Bhabha Atomic Research Centre (BARC), Trombay, Mumbai 400 085 India
| | | | - Furn F Knapp
- Medical Isotopes Program, Isotope Development Group, Oak Ridge National Laboratory (ORNL), P.O. Box 2008, MS 6229, Bldg, 4501, 1 Bethel Valley Road,, Oak Ridge, TN 37831-6229 USA
| |
Collapse
|
37
|
|
38
|
The status of radioimmunotherapy in CD20+ non-Hodgkin's lymphoma. Target Oncol 2014; 10:15-26. [PMID: 24870968 DOI: 10.1007/s11523-014-0324-y] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2014] [Accepted: 05/19/2014] [Indexed: 01/30/2023]
Abstract
Rituximab, the CD20-directed antibody, has become a standard component of treatment regimens for patients with B cell non-Hodgkin's lymphoma (NHL). The use of rituximab has resulted in greatly improved response and survival rates with less toxicity relative to standard chemotherapeutic regimes. However, relapse and recurrence is common, particularly in indolent varieties which remain incurable, requiring alternate therapeutic options. The subsequent coupling of β-emitting isotopes such as (131)I and (90)Y to anti-CD20 monoclonal antibodies (mAbs), including rituximab, has been steadily growing over the last decade and demonstrates even greater therapeutic efficacy with more durable responses. (177)Lutetium-labelled rituximab offers a number of convenient advantages over (131)I and (90)Y anti-CD20 mAbs for treatment of NHL, and a number of alpha-emitting isotopes lie at the frontier of consolidation therapy for residual, micrometastatic disease.
Collapse
|
39
|
Abstract
Abstract
Medical radionuclide production technology is well established. Both reactors and cyclotrons are utilized for production; the positron emitters, however, are produced exclusively using cyclotrons. A brief survey of the production methods of most commonly used diagnostic and therapeutic radionuclides is given. The emerging radionuclides are considered in more detail. They comprise novel positron emitters and therapeutic radionuclides emitting low-range electrons and α-particles. The possible alternative production routes of a few established radionuclides, like 68Ga and 99mTc, are discussed. The status of standardisation of production data of the commonly used as well as of some emerging radionuclides is briefly mentioned. Some notions on anticipated future trends in the production and application of radionuclides are considered.
Collapse
Affiliation(s)
- S. M. Qaim
- Institut für Neurowissenschaften und Medizin, INM-5: Nuklearchemie, Forschungszentrum Jülich GmbH, 52425 Jülich, Germany
| |
Collapse
|
40
|
Müller C, Reber J, Haller S, Dorrer H, Bernhardt P, Zhernosekov K, Türler A, Schibli R. Direct in vitro and in vivo comparison of 161Tb and 177Lu using a tumour-targeting folate conjugate. Eur J Nucl Med Mol Imaging 2013; 41:476-85. [DOI: 10.1007/s00259-013-2563-z] [Citation(s) in RCA: 65] [Impact Index Per Article: 5.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2013] [Accepted: 08/27/2013] [Indexed: 11/28/2022]
|
41
|
Das T, Pillai M. Options to meet the future global demand of radionuclides for radionuclide therapy. Nucl Med Biol 2013; 40:23-32. [DOI: 10.1016/j.nucmedbio.2012.09.007] [Citation(s) in RCA: 61] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2012] [Revised: 09/05/2012] [Accepted: 09/10/2012] [Indexed: 01/09/2023]
|
42
|
Abstract
The aim of this study was to evaluate acyclic ligands which can be applied for labeling proteins such as monoclonal antibodies and their fragments with scandium radionuclides. Recently, scandium isotopes (47Sc, 44Sc) are more available and their properties are convenient for radiotherapy or PET imaging. They can be used together as “matched pair” in theranostic approach. Because proteins denaturize at temperature above 42 °C, ligands which efficiently form complexes at room temperature, are necessary for labelling such biomolecules. For complexation of scandium radionuclides open chain ligands DTPA, HBED, BAPTA, EGTA, TTHA and deferoxamine have been chosen. We found that the ligands studied (except HBED) form strong complexes within 10 min and that the radiolabelling yield varies between 96 and 99 %. The complexes were stable in isotonic NaCl, but stability of 46Sc-TTHA, 46Sc-BAPTA and 46Sc-HBED in PBS buffer was low, due to formation by Sc3+stronger complexes with phosphates than with the studied ligands. From the radiolabelling studies with n.c.a. 47Sc we can conclude that the most stable complexes are formed by the 8-dentate DTPA and EGTA ligands.
Collapse
|
43
|
Abstract
Abstract
Radionuclides with medium energy beta emission and a several day half-life are attractive candidates for radioimmunotherapy. Among the most promising in this category is 47Sc produced by fast neutron irradiation (E
n>1 MeV) of titanium target with high energy neutrons in 47Ti(n,p) 47Sc nuclear reaction. In the previously reported production scheme the dissolution of the TiO2 target in hot concentrated H2SO4 and evaporation of the resulting solution were the most time-consuming steps. The present paper describes new, simple and efficient production method of 47Sc, where the slow dissolution of the target is avoided. After irradiation in fast neutron flux 47TiO2 and Li2
47TiF6 targets were dissolved in HF solutions. Next 47Sc was separated from the target using anion exchange resin Dowex 1 with 0.4 M HF + 0.06 M HNO3 solution as eluent. The eluted 47Sc was adsorbed on cation exchange resin and eluted with 0.5 M of ammonium acetate. The 47Sc separation yield in the proposed procedure is about 90% with the separation time less than 2 h. The obtained no-carrier-added 47Sc was used to label DOTATATE conjugate with 96% labeling yield.
Collapse
|
44
|
Nassan L, Achkar B, Yassine T. Nuclear chemical transformations of ytterbium and lutetium radionuclides following (n,γ) and beta decay reactions in Tris(2,2,6,6-tetramethyle-3,5-heptanedionato)Yb(III). Appl Radiat Isot 2012; 70:563-7. [DOI: 10.1016/j.apradiso.2011.11.060] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2011] [Revised: 10/30/2011] [Accepted: 11/29/2011] [Indexed: 10/14/2022]
|
45
|
Chakravarty R, Das T, Venkatesh M, Dash A. An electro-amalgamation approach to produce 175Yb suitable for radiopharmaceutical applications. RADIOCHIM ACTA 2012. [DOI: 10.1524/ract.2012.1915] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
Abstract
175Yb is a prospective reactor produced radionuclide suitable for preparation of therapeutic radiopharmaceuticals. However, a major restraint in the use of 175Yb produced via the (n, γ) reaction, for therapeutic applications, is the presence of longer-lived 177Lu impurity which is co-produced along with 175Yb on irradiation of natural Yb2O3 target. A radiochemical separation procedure adopting electro-amalgamation approach for the removal of 177Lu impurity from 175Yb has been critically evaluated. The experimental parameters such as applied potential, electrolysis time and the pH of the electrolyte, affecting the electrochemical separation process, were studied and optimized. The developed radiochemical procedure was extensively tested for purification of up to 15 GBq of 175Yb. The purified 175Yb could be obtained in HCl medium with ∼95% yield. The 177Lu impurity could not be detected in the purified product and 175Yb was found suitable for the preparation of potential radiotherapeutic agents.
Collapse
Affiliation(s)
| | - Tapas Das
- Bhabha Atomic Research Centre, Radiopharmaceuticals Division, Trombay, Mumbai 400085, Indien
| | - Meera Venkatesh
- Bhabha Atomic Research Centre, Radiopharmaceuticals Division, Trombay, Mumbai 400085, Indien
| | | |
Collapse
|
46
|
Banerjee S, Das T, Chakraborty S, Venkatesh M. Emergence and present status of Lu-177 in targeted radiotherapy: the Indian scenario. ACTA ACUST UNITED AC 2011. [DOI: 10.1524/ract.2011.1843] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
Abstract
177Lu is presently considered to be a potential radionuclide for the development of agents for radionuclide therapy owing to its favorable nuclear decay characteristics [T
1/2 = 6.65 d, E
β(max) = 0.497 MeV, E
γ
= 113 KeV (6.4%) and 208 KeV (11%)]. While the long half-life of this promising radioisotope offers distinct logistic advantage, particularly, in countries having limited reactor facilities, the feasibility of its large-scale production with adequate specific activity and excellent radionuclidic purity in medium flux research reactors constitute yet another desirable feature. Extensive studies have been carried out to optimize the production of this isotope, with high specific activity and radionuclidic purity by the (n,γ) route using the highest available flux and the optimum irradiation time. The gradual evolution of clin ical grade 177LuCl3 as a new radiochemical, ready for commercial deployment by Radiopharmaceuticals Division, Bhabha Atomic Research Centre, to nuclear medicine centers all over India was accomplished in 2010 in a stepwise manner with the commencement of the production of high specific activity 177Lu from enriched target in 2001. Research on 177Lu has demonstrated its immense potential in radiotherapeutic applications, a direct outcome of which has resulted in indigenous development of two agents viz.
177Lu-EDTMP and 177Lu-DOTA-TATE presently being evaluated in human patients for palliative care of bone pain due to skeletal metastases and treatment of malignancies of neuroendocrine origin, respectively. Using locally produced 177Lu, the radiolabeling of a plethora of other molecules with potential applicability in radiation synovectomy and targeted therapy of malignant tumors have been successfully demonstrated. A few of these agent such as a novel 177Lu-labeled porphyrin has shown considerable promise in initial studies and is presently evaluated. In the present article, our research efforts toward standardization of production methodology of 177Lu in high specific activity and its utilization in the devel opment of agents for targeted radiotherapy are being reported.
Collapse
Affiliation(s)
| | - Tapas Das
- Bhabha Atomic Research Centre, Radiopharmaceuticals Division, Trombay, Mumbai 400085, Indien
| | - S. Chakraborty
- Bhabha Atomic Research Centre, Radiopharmaceuticals Division, Trombay, Mumbai 400085, Indien
| | - Meera Venkatesh
- Bhabha Atomic Research Centre, Radiopharmaceuticals Division, Trombay, Mumbai 400085, Indien
| |
Collapse
|
47
|
Majkowska-Pilip A, Bilewicz A. Macrocyclic complexes of scandium radionuclides as precursors for diagnostic and therapeutic radiopharmaceuticals. J Inorg Biochem 2010; 105:313-20. [PMID: 21194633 DOI: 10.1016/j.jinorgbio.2010.11.003] [Citation(s) in RCA: 97] [Impact Index Per Article: 6.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2010] [Revised: 11/04/2010] [Accepted: 11/05/2010] [Indexed: 11/30/2022]
Abstract
The aim of this study was to evaluate new ligands which can be applied for labeling biomolecules with scandium radionuclides. Two radionuclides of scandium, (47)Sc and (44)Sc, are perspective radioisotopes for radiotherapy and diagnostic imaging. (47)Sc decays with a half-life of 3.35 days and a maximum β(-) energy of 600 keV and could be an alternative to carrier added (177)Lu radionuclide for targeted radionuclide therapy. Another scandium radionuclide (44)Sc (t(1/2) = 3.92 h) is an ideal β(+) emitter for PET diagnosis. It can be obtained as a daughter of the long-lived (44)Ti (t(1/2) = 60.4 y) from (44)Ti/(44)Sc generator. For complexation of scandium radionuclides macrocyclic ligands having a cavity size similar to Sc(3+) ionic radius were selected: 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), 1,4,7-triazacyclononane-1,4,7 triacetic acid (NOTA), 1,4,7-triazacyclodecane-1,4,7 triacetic acid and 1,4,7-triazacycloundecane triacetic acid, and analogs of NOTA with 10, 11 and 12 atoms of the carbon in the ring. Our results have shown that from the studied macrocyclic ligands studied DOTA is most efficient for binding scandium radionuclides (44)Sc and (47)Sc to biomolecules. The determined stability constant of Sc-DOTA complex logK = 27.0 is comparable with stability constants for Y(3+) and heaviest lanthanides but is higher than those for In(3+) and Ga(3+). Also (46)Sc-DOTATATE conjugate exhibits high stability in-vitro studies. The (13)C NMR studies have shown that Sc-DOTA like Lu-DOTA forms in solution complexes with eight-coordination geometry. The lipophilicity of Sc-DOTATATE is nearly identical to that of Lu-DOTATATE, which suggests similar receptor affinity of both radioconjugates.
Collapse
Affiliation(s)
- A Majkowska-Pilip
- Institute of Nuclear Chemistry and Technology, Centre of Radiochemistry and Nuclear Chemistry, Dorodna 16, 03-195 Warsaw, Poland.
| | | |
Collapse
|
48
|
An electro-amalgamation approach to isolate no-carrier-added 177Lu from neutron irradiated Yb for biomedical applications. Nucl Med Biol 2010; 37:811-20. [DOI: 10.1016/j.nucmedbio.2010.04.082] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2009] [Revised: 04/07/2010] [Accepted: 04/07/2010] [Indexed: 11/20/2022]
|
49
|
|
50
|
Separation of Yb as YbSO4 from the 176Yb target for production of 177Lu via the 176Yb(n, γ)177Yb→177Lu process. J Radioanal Nucl Chem 2009. [DOI: 10.1007/s10967-008-7437-7] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|